Department of Clinical Oncology, Translational Oncology Unit, Università Politecnica delle Marche, AOU "Ospedali Riuniti", Via Conca 71, 60020 Ancona, Italy.
Cancer Treat Rev. 2014 Sep;40(8):934-41. doi: 10.1016/j.ctrv.2014.06.004. Epub 2014 Jun 20.
The number of anti-angiogenic drugs who demonstrated activity in metastatic colorectal cancer patients is arising but there is still much debate on which is the optimal use of this class of agents, with particular emphasis given on when (meant as in which line of treatment) and how (meant as in duration of treatment). We sampled the data of randomised phase II-III trials employing this type of drugs, with particular emphasis on trying to "highlight" situations where anti-angiogenetic treatment could provide most benefit. The review displays all relevant clinical data regarding the use of anti-angiogenic drugs in metastatic colorectal cancer and comments on potential implications of these trials in everyday clinical practice.
抗血管生成药物在转移性结直肠癌患者中显示出疗效的数量正在增加，但对于这类药物的最佳使用方法仍存在很多争议，特别是在何时（意味着在治疗的哪一线）和如何（意味着治疗的持续时间）方面。我们对使用这类药物的随机 II-III 期试验的数据进行了抽样，特别强调了试图“突出”抗血管生成治疗可能提供最大益处的情况。该综述展示了转移性结直肠癌中使用抗血管生成药物的所有相关临床数据，并对这些试验在日常临床实践中的潜在影响进行了评论。
